Similar articles for PMID: 22452603

Year	Number of Results
2001	1
2002	5
2003	7
2004	3
2005	8
2006	10
2007	3
2008	1
2009	5
2010	3
2011	2
2012	6
2013	4
2014	3
2015	14
2016	14
2017	7
2018	5
2019	1
2020	4
2021	2
2022	2
2024	0

1

Antagonizing IL-6 in ankylosing spondylitis: a short review.

Rajalingham S, Das S. Rajalingham S, et al. Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):262-5. doi: 10.2174/187152812800958979. Inflamm Allergy Drug Targets. 2012. PMID: 22452603 Review.

2

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS. Schoels MM, et al. Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Ann Rheum Dis. 2013. PMID: 23144446 Free PMC article. Review.

3

Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.

Siebert S, Tsoukas A, Robertson J, McInnes I. Siebert S, et al. Pharmacol Rev. 2015;67(2):280-309. doi: 10.1124/pr.114.009639. Pharmacol Rev. 2015. PMID: 25697599 Review.

4

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Braun J, et al. Curr Opin Rheumatol. 2003 Jul;15(4):394-407. doi: 10.1097/00002281-200307000-00005. Curr Opin Rheumatol. 2003. PMID: 12819466 Review.

5

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group. Braun J, et al. Ann Rheum Dis. 2006 Mar;65(3):316-20. doi: 10.1136/ard.2005.040758. Epub 2005 Aug 11. Ann Rheum Dis. 2006. PMID: 16096329 Free PMC article.

6

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T. McLeod C, et al. Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280. Health Technol Assess. 2007. PMID: 17651658 Free article. Review.

7

Biologics in Inflammatory and Immunomediated Arthritis.

Luchetti MM, Benfaremo D, Gabrielli A. Luchetti MM, et al. Curr Pharm Biotechnol. 2017;18(12):989-1007. doi: 10.2174/1389201019666171226151852. Curr Pharm Biotechnol. 2017. PMID: 29278210 Review.

8

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group. Braun J, et al. Ann Rheum Dis. 2003 Sep;62(9):817-24. doi: 10.1136/ard.62.9.817. Ann Rheum Dis. 2003. PMID: 12922952 Free PMC article. Review.

9

Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis.

Garg N, Krishan P, Syngle A. Garg N, et al. Clin Rheumatol. 2015 Jun;34(6):1065-71. doi: 10.1007/s10067-015-2912-3. Epub 2015 Mar 17. Clin Rheumatol. 2015. PMID: 25771851 Clinical Trial.

10

An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D. Pham T, et al. Ann Rheum Dis. 2006 Dec;65(12):1620-5. doi: 10.1136/ard.2005.042630. Epub 2006 Feb 7. Ann Rheum Dis. 2006. PMID: 16464984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year